Advertisement
MRNA vs PCVX
Which Stock Would AI Choose? Moderna (MRNA) vs. Vaxcyte (PCVX) Stock Comparison
Key Takeaways
- Both MRNA and PCVX operate in the biotech vaccine sector, with Moderna leveraging commercial mRNA products and Vaxcyte advancing Phase 3 clinical candidates.
- Moderna has delivered stronger year-to-date gains of approximately 64%, outpacing Vaxcyte's 31% rise amid recent market activity.
- Vaxcyte benefits from fresh Phase 3 trial enrollment completions for its lead pneumococcal vaccine, signaling near-term catalysts.
- Analysts project greater upside for Vaxcyte, with an average price target implying over 80% potential increase compared to Moderna's modest outlook.
- Both stocks trade at elevated valuations without profits, highlighting risks tied to clinical and regulatory outcomes in biotech.
Introduction
This stock comparison examines MRNA and PCVX, two biotech innovators in vaccine development. Moderna represents established mRNA technology with commercial revenues, while Vaxcyte focuses on next-generation bacterial vaccines in late-stage trials. Traders seeking momentum in healthcare and investors eyeing biotech growth drivers will find value in analyzing their relative performance, pipeline progress, and market positioning amid evolving sector sentiment.
MRNA Overview and Recent Performance
Moderna, Inc. (MRNA) pioneers messenger RNA (mRNA) medicines, offering products like Spikevax for COVID-19 and mRESVIA for respiratory syncytial virus (RSV). Its pipeline spans respiratory vaccines, oncology therapeutics, and rare diseases through partnerships with Merck and others. In recent market activity, shares have surged over 64% year-to-date, trading around $48.60 with a market cap exceeding $19 billion. This momentum reflects pipeline advancements, including H5N1 vaccine developments and upcoming earnings, though sentiment tempers due to negative EPS (-7.26 TTM, or trailing twelve months) and Zacks Rank #3 (Hold). Volatility persists as investors weigh commercial execution against R&D costs.
PCVX Overview and Recent Performance
Vaxcyte, Inc. (PCVX) is a clinical-stage firm developing conjugate vaccines against bacterial diseases, led by VAX-31 and VAX-24 pneumococcal conjugate vaccines (PCVs, vaccines targeting pneumococcal bacteria). Early pipeline assets address Group A Streptococcus and shigellosis. Recent weeks saw shares rise about 31% year-to-date to roughly $60.40, with a $8.7 billion market cap. Key sentiment boost came from completing enrollment in OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, evaluating invasive pneumococcal disease prevention. Despite negative EPS (-5.63 TTM), strong analyst buy ratings and a $109 average target underscore optimism, though pre-revenue status amplifies trial risks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top performers, curating 25 bots from over 351 total AI trading agents suited to current market dynamics. These bots employ diverse strategies—signal agents, virtual agents, and brokerage agents—across timeframes like 60-minute, 15-minute, and 5-minute charts, trading thousands of tickers with varying styles from short-term scalping to longer holds. Performance highlights include competitive win rates, profit factors, and returns tailored to volatile conditions, helping traders replicate proven patterns. Explore these tools to enhance decision-making in dynamic markets like biotech.
Head-to-Head Comparison
Moderna’s business model centers on commercialized mRNA platforms generating revenue, contrasting Vaxcyte’s pre-commercial focus on innovative PCVs for underserved bacterial threats. Growth drivers diverge: MRNA leverages broad pipeline diversification into flu combos and oncology, while PCVX banks on Phase 3 data superiority over existing PCVs. Recent momentum favors Moderna’s steadier gains, but Vaxcyte shows sharper upside potential per targets. Risks include regulatory hurdles for Vaxcyte and profitability pressures for Moderna amid high R&D burn. Both expose investors to healthcare sector volatility, with sentiment tilting toward clinical catalysts for PCVX versus Moderna’s established traction.
Tickeron AI Verdict
Tickeron’s AI currently leans toward PCVX based on consistent Phase 3 progress, superior analyst consensus, and relative positioning for breakout catalysts in pneumococcal vaccines. While MRNA offers stability through revenues, Vaxcyte’s momentum and upside suggest higher probability of outperformance in the near term, contingent on trial outcomes and market reception.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a StrongBuy and PCVX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 2 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).
- MRNA’s FA Score: 2 green, 3 red.
- PCVX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 5 TA indicator(s) are bullish while PCVX’s TA Score has 4 bullish TA indicator(s).
- MRNA’s TA Score: 5 bullish, 5 bearish.
- PCVX’s TA Score: 4 bullish, 4 bearish.
Price Growth
MRNA (@Biotechnology) experienced а +13.84% price change this week, while PCVX (@Biotechnology) price change was +5.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.
Reported Earning Dates
MRNA is expected to report earnings on Jul 30, 2026.
PCVX is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (+5.89% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MRNA | PCVX | MRNA / PCVX | |
| Capitalization | 24.2B | 7.5B | 323% |
| EBITDA | -2.88B | -1.06B | 271% |
| Gain YTD | 101.238 | 12.939 | 782% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 2.2B | 0 | - |
| Total Cash | 5.21B | 1.74B | 300% |
| Total Debt | 1.3B | 116M | 1,119% |
MRNA | PCVX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 3 | 48 | |
P/E GROWTH RATING 1..100 | 2 | 49 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCVX's Valuation (66) in the null industry is in the same range as MRNA (78) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
PCVX's Profit vs Risk Rating (77) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
PCVX's SMR Rating (98) in the null industry is in the same range as MRNA (98) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's Price Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for PCVX (48) in the null industry. This means that MRNA’s stock grew somewhat faster than PCVX’s over the last 12 months.
MRNA's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for PCVX (49) in the null industry. This means that MRNA’s stock grew somewhat faster than PCVX’s over the last 12 months.
| MRNA | PCVX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 76% |
| Advances ODDS (%) | 6 days ago 79% | 2 days ago 78% |
| Declines ODDS (%) | 22 days ago 87% | 16 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 81% |
Advertisement
MRNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with NVAX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then NVAX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | -7.22% | ||
| NVAX - MRNA | 53% Loosely correlated | -1.42% | ||
| BNTX - MRNA | 50% Loosely correlated | -0.77% | ||
| MRVI - MRNA | 44% Loosely correlated | +1.15% | ||
| PCVX - MRNA | 43% Loosely correlated | +1.30% | ||
| CRSP - MRNA | 43% Loosely correlated | +0.50% | ||
More | ||||
PCVX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with VIR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To PCVX | 1D Price Change % | ||
|---|---|---|---|---|
| PCVX | 100% | +1.30% | ||
| VIR - PCVX | 53% Loosely correlated | +4.48% | ||
| DNLI - PCVX | 49% Loosely correlated | +3.17% | ||
| BCYC - PCVX | 49% Loosely correlated | -0.63% | ||
| BCAX - PCVX | 46% Loosely correlated | +5.73% | ||
| AVBP - PCVX | 45% Loosely correlated | +3.02% | ||
More | ||||